Sotac Pharmaceuticals Ltd
SOTACSotac Pharmaceuticals Ltd
SOTAC
Price Chart
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 27.12 | 2.47 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.92 | 6.65 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
The Company specializes in the manufacturing of a range of pharmaceutical products, such as Non Beta-Lactam (general) tablets, Non Beta-Lactam (general) capsules, Non Beta-Lactam syrup, and external preparations.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2023 | FY 2024 | TTM | |||
|---|---|---|---|---|---|---|
| Total Revenue | 77.83 | 104.32 | 106.45 | |||
Raw Materials | 61.68 | 80.37 | 96.60 | |||
| Power & Fuel Cost | 1.37 | 1.98 | ||||
| Employee Cost | 2.58 | 2.05 | ||||
| Selling & Administrative Expenses | 4.23 | 4.39 | ||||
| Operating & Other expenses | -0.27 | 6.72 | ||||
EBITDA | 8.24 | 8.81 | 9.85 | |||
| Depreciation/Amortization | 2.28 | 3.10 | 3.20 | |||
| PBIT | 5.96 | 5.71 | 6.65 | |||
| Interest & Other Items | 2.04 | 1.74 | 2.36 | |||
| PBT | 3.92 | 3.97 | 4.29 | |||
| Taxes & Other Items | 1.05 | -0.31 | -0.20 | |||
| Net Income | 2.87 | 4.28 | 4.49 | |||
| EPS | 3.57 | 4.48 | 4.06 | |||
| DPS | 0.00 | — | 0.00 | |||
| Payout ratio | 0.00 | 0.00 | 0.00 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Sotac Pharmaceuticals Ltd | 28.45 | 2.47 | — |
| Sun Pharmaceutical Industries Ltd | 45.12 | 6.44 | 0.75% |
| Cipla Ltd | 28.85 | 4.44 | 0.88% |
| Torrent Pharmaceuticals Ltd | 69.10 | 16.69 | 0.83% |
Price Comparison
Compare SOTAC with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
No institutional holdings trend are available
Shareholding Pattern
Apr 2023
Sep 2023
Mar 2024
Sep 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
SOTAC has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeSotac Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 29 October 2024Powered by Capital Market - Live
Sotac Pharmaceuticals announced that the 9th Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
Net profit of Sotac Pharmaceuticals rose 34.26% to Rs 1.45 crore in the quarter ended June 2024 as against Rs 1.08 crore during the previous quarter ended June 2023. Sales rose 1.12% to Rs 25.25 crore in the quarter ended June 2024 as against Rs 24.97 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales25.2524.97 1 OPM %8.759.37 - PBDT2.052.11 -3 PBT1.301.50 -13 NP1.451.08 34 Powered by Capital Market - Live
Sotac Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant